Author

Ricardo de Matos Simoes

Dana Farber Cancer Institute - Cited by 1,756 - Computational Cancer Biology

Biography

Dr. Ricardo de Matos Simoes is an associate professor works at the Centre for Cancer Research & Cell Biology, Queens University Belfast, Northern Ireland and recent publication include Urinary  Thrombomodulin  Levels  Were  Significantly  Higher  Following  Occupational Exposure to Chemicals, In The Presence of Dipstick Protein,  But Not in the Presence of Dipstick Blood
Title
Cited by
Year
An embryonic diapause-like adaptation with suppressed Myc activity enables tumor treatment persistence
E Dhimolea, R de Matos Simoes, D Kansara, A Al’Khafaji, J Bouyssou, ...Cancer cell 39 (2), 240-256. e11, 2021202
101
2021
Functional genomics identify distinct and overlapping genes mediating resistance to different classes of heterobifunctional degraders of oncoproteins
R Shirasaki, GM Matthews, S Gandolfi, R de Matos Simoes, DL Buckley, ...Cell Reports 34 (1), 2021202
41
2021
Genome-scale screens identify factors regulating tumor cell responses to natural killer cells
M Sheffer, E Lowry, N Beelen, M Borah, SNA Amara, CC Mader, JA Roth, ...Nature Genetics 53 (8), 1196-1206, 2021202
37
2021
Assessment of Nuclear ZEB2 as a Biomarker for Colorectal Cancer Outcome and TNM Risk Stratification
R Sreekumar, S Harris, K Moutasim, R de Matos Simoes, A Patel, K Emo, ...JAMA Network Open 1 ((6), e183115), 2018201
27
2018
A Genome-Wide Drosophila Epithelial Tumorigenesis Screen Identifies Tetraspanin 29Fb as an Evolutionarily Conserved Suppressor of Ras-driven Cancer
T Zoranovic, J Manent, L Willoughby, R Matos de Simoes, JE La Marca, ...PLoS Genetics 14 ((10):e1007688), 2018201
12
2018
Prostate cancer gene regulatory network inferred from RNA-seq data
D Moore, R de Matos Simoes, M Dehmer, F Emmert-StreibCurrent Genomics 20 (1), 38-48, 2019201
12
2019
Pleiotropic mechanisms drive endocrine resistance in the three-dimensional bone microenvironment
E Dhimolea, R de Matos Simoes, D Kansara, X Weng, S Sharma, P Awate, ...Cancer research 1 (2), 371-33, 2021202
8
2021
Pharmacological perturbation of the immunoproteasome in hematologic neoplasias: therapeutic implications
SL Downey-Kopyscinski, RDM Simoes, M Bariteau, ML Borah, S Bender, ...Blood 14, 1291, 2019201
3
2019
Systematic characterization of genes representing preferential molecular vulnerabilities for myeloma cells compared to other neoplasias-implications for the biology and …
RDM Simoes, R Shirasaki, SL Downey-Kopyscinski, G Matthews, H Yiguo, ...Blood 14, 4407, 2019201
3
2019
TSPAN6 is a suppressor of Ras-driven cancer
PO Humbert, TZ Pryjda, B Pranjic, A Farrell, K Fujikura, ...Oncogene 41 (14), 2095-2105, 2022202
3
2022
POU2AF1 as a master regulator of oncogenic transcription factor networks in myeloma
POUAF1 as a master regulator of oncogenic transcription factor networks in myelomaRDM Simoes, R Shirasaki, H Tang, S Yamano, BG Barwick, S Gandolfi, ...Blood 136, 18-19, 000
2
2020
Functional genomic landscape of genes with recurrent mutations in multiple myeloma
RDM Simoes, R Shirasaki, H Tang, M Sheffer, O Dashevsky, S Gandolfi, ...Blood 13, 189, 01801
2
2018
Molecular markers of MM cell sensitivity and resistance to natural killer cells: implications for anti-MM immunotherapy
S Gandolfi, M Sheffer, E Lowry, O Dashevsky, R Shirasaki, ...Clinical Lymphoma, Myeloma and Leukemia 9 (0), e68-e69, 20920
1
2019
Molecular markers of myeloma cell sensitivity vs. resistance to heterobifunctional degraders of oncoproteins: therapeutic implications.
R Shirasaki, R de Matos Simoes, S Gandolfi, G Matthews, D Buckley, ...Clinical Lymphoma, Myeloma and Leukemia 9 (0), e34, 20920
1
2019
Diagnosis of urothelial cancer
M Ruddock, C Reid, J LaMont, S Fitzgerald, RDM Simoes, K WilliamsonUS Patent 0,68,33, 20920
1
2019
Use of olfactory receptor genes as controls for genome-scale CRISPR functional genomic studies to define treatment resistance mechanisms
O Dashevsky, RDM Simoes, R Shirasaki, M Sheffer, E Dhimolea, ...Blood 36, 36, 2020202
1
2020
CRISPR Activation Screen for HDAC Inhibitor Resistance
H Tang, RDM Simoes, R Shirasaki, O Dashevsky, B Glassner, ...Blood 32, 3958, 20820
1
2018
OAB-019: CRISPR screens with single-cell transcriptome readout reveal potential mechanisms of response to natural killer cell treatment in multiple myeloma
OAB-09: CRISPR screens with single-cell transcriptome readout reveal potential mechanisms of response to natural killer cell treatment in multiple myelomaS Gandolfi, O Dufva, J Huuhtanen, O Dashevsky, J Klievink, J Bouhlal, ...Clinical Lymphoma Myeloma and Leukemia 2, S2-S3, 20220
1
2021
Single-cell functional genomics of natural killer cell evasion in blood cancers
O Dufva, S Gandolfi, J Huuhtanen, O Dashevsky, K Saeed, J Klievink, ...bioRxiv, 2022.08. 22.504722, 2022202
1
2022

Referred From: https://scholar.google.com/citations?user=xovuT6sAAAAJ

Cited by
Citations 1756
h-index 21
i10-index 26
Recommended Journals
Open Access Journals